Details of the Drug

General Information of Drug (ID: DM3PBMR)

Drug Name
INTERCEPT
Indication
Disease Entry ICD 11 Status REF
Blood transfusion QB98 Phase 3 [1]
Infectious disease 1A00-CA43.1 Phase 2 [2]
Structure
3D MOL 2D MOL
Cross-matching ID
PubChem CID
72385
TTD ID
D05JFA
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 Clinical pipeline report, company report or official report of Cerus.
2 ClinicalTrials.gov (NCT02310412) A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma. U.S. National Institutes of Health.